Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone

Open access
Day, Kathleen C., Hiles, Guadalupe Lorenzatti, Kozminsky, Molly, Dawsey, Scott J., Paul, Alyssa, Broses, Luke J., Shah, Rajal, Kunja, Lakshmi P., Hall, Christopher, Palanisamy, Nallasivam, Daignault-Newton, Stephanie, El-Sawy, Layla, Wilson, Steven James, Chou, Andrew, Ignatoski, Kathleen Woods, Keller, Evan, Thomas, Dafydd, Nagrath, Sunitha, Morgan, Todd, Day, Mark L. · 2017 · Cancer Research

Abstract

Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the progression of multiple cancer types through complex mechanisms that are still not fully understood. In this study, we report that HER2 expression is elevated in bone metastases of prostate cancer independently of gene amplification. An examination of HER2 and NF-κB receptor (RANK) coexpression revealed increased levels of both proteins in aggressive prostate tumors and metastatic deposits. Inhibiting HER2 expression in bone tumor xenografts reduced proliferation and RANK expression while maintaining EGFR expression. In examining the role of EGFR in tumor-initiating cells (TIC), we found that EGFR expression was required for primary and secondary sphere formation of prostate cancer cells. EGFR expression was also observed in circulating tumor cells (CTC) during prostate cancer metastasis. Dual inhibition of HER2 and EGFR resulted in significant inhibition of tumor xenograft growth, further supporting the significance of these receptors in prostate cancer progression. Overall, our results indicate that EGFR promotes survival of prostate TIC and CTC that metastasize to bone, whereas HER2 supports the growth of prostate cancer cells once they are established at metastatic sites. Cancer Res; 77(1); 74–85. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-1656

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 183

Metadata

Authors
Day, K. C., Hiles, G. L., Kozminsky, M., Dawsey, S. J., Paul, A., Broses, L. J., Shah, R., Kunja, L. P., Hall, C., Palanisamy, N., Daignault-Newton, S., El-Sawy, L., Wilson, S. J., Chou, A., Ignatoski, K. W., Keller, E., Thomas, D., Nagrath, S., Morgan, T., & Day, M. L.
Venue
Cancer Research
Published
2017-01-01
Volume
77
Issue
1
Pages
74-85
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2545169478
Cited by
183
References
2
FWCI
12.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-1656
The paper
Day, K. C., Hiles, G. L., Kozminsky, M., Dawsey, S. J., Paul, A., Broses, L. J., Shah, R., Kunja, L. P., Hall, C., Palanisamy, N., Daignault-Newton, S., El-Sawy, L., Wilson, S. J., Chou, A., Ignatoski, K. W., Keller, E., Thomas, D., Nagrath, S., Morgan, T., & Day, M. L. (2017). HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-1656

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.